Trial Profile
A Multicenter Randomized Double-Blind Active Controlled Parallel Group Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 01 Nov 2016 Results of a pooled post-hoc analysis of five phase IIb and 16 phase III studies (including this study) assessing frequency and characteristics of hypersensitivity adverse events, published in the Clinical Drug Investigation.
- 05 Oct 2012 Pooled analysis assessing the effect of dapagliflozin treatment on renal function presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 13 Mar 2012 Results published in the International Journal of Clinical Practice.